Standard BioTools Inc (NAS:LAB)
$ 1.82 -0.08 (-4.21%) Market Cap: 707.29 Mil Enterprise Value: 404.38 Mil PE Ratio: 0 PB Ratio: 1.45 GF Score: 51/100

Fluidigm Corp at UBS Global Healthcare Conference Transcript

May 21, 2019 / 03:30PM GMT
Release Date Price: $11.9 (-1.98%)
Daniel Gregory Brennan
UBS Investment Bank, Research Division - Senior Equity Research Analyst of Healthcare Life Sciences

Great. Well, welcome. Welcome to day 2 kind of late in the morning of the UBS Global Healthcare Conference 2019. Pleased you're all here. I'm Dan Brennan. I cover the life science tool diagnostics pharma services. I'm pleased to be joined on stage by Chris Linthwaite. I hope I pronounced it right, Chris. I know we've done many calls together already during my initiation process. Chris, CEO of Fluidigm. And in the audience, we have Agnes Lee, who's IR.

So listen, I have a series of questions prepared. Would love any audience participation here who's willing to step up. So I'll look up during the presentation.

Before we get started, just you could go to UBS website at www.ubs.com, where you could see the analyst disclaimer information.

So I thought I kick off with just a high-level question, Chris, if you don't mind, and I know you've been with the company now a couple of years and certainly has

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot